AMG 837: a potent, orally bioavailable GPR40 agonist

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1267-70. doi: 10.1016/j.bmcl.2011.10.118. Epub 2011 Nov 6.

Abstract

The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of β-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.

MeSH terms

  • Administration, Oral
  • Animals
  • Biological Availability
  • Biphenyl Compounds / administration & dosage
  • Biphenyl Compounds / chemistry
  • Biphenyl Compounds / pharmacology*
  • Dose-Response Relationship, Drug
  • Mice
  • Mice, Knockout
  • Molecular Structure
  • Receptors, G-Protein-Coupled / agonists*
  • Receptors, G-Protein-Coupled / deficiency
  • Receptors, G-Protein-Coupled / metabolism
  • Stereoisomerism
  • Structure-Activity Relationship

Substances

  • AMG 837
  • Biphenyl Compounds
  • Ffar1 protein, mouse
  • Receptors, G-Protein-Coupled